Fremanezumab Phase III Migraine Trial

Fremanezumab is a drug being developed by Teva Pharmaceuticals for the prevention of migraine. Fremanezumab is a monocolonal antibody and a biological agent that binds to and blocks the action of a migraine-associated protein called calcitonin gene-related peptide (CGRP).  Results of the phase III clinical trial were published in Nov., 2017, in the New England Journal of Medicine. This study showed that fremanezumab was found successful in reducing the number of days that chronic migraine sufferers experienced headaches. It is estimated that between 127 and 300 million people in the entire world experience chronic migraine, with 15 or more headaches per month for at least three months. Those who experience such intense and chronic migraines have a tough time finding effective relief. As such fremanezumab has been developed to hopefully help those who suffer and do not have any current medication that is effective. … Read more